2 genes cooperate to cause aggressive leukemia

	Tweet

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.

The two genes are often present in mutated form in acute leukaemias, but the mutations rarely occur together. Scientists have previously believed that the two mutated genes have exactly the same function: each one alone will lead to increased activity of a carcinogenic protein known as “RAS”. This protein, in turn, causes blood cells to proliferate more rapidly.

“This is a surprising discovery that suggests that there is a mechanism behind the development of cancer that has not yet been recognised. It opens the way for new methods of fighting blood cancer cells with NF1 mutations”, says Associate professor Martin Bergö, who leads the research at the Wallenberg Laboratory at the Sahlgrenska Academy.

One of the genes codes for the RAS protein, which is a known accelerator for cell proliferation in several forms of cancer. The other gene codes for a protein known as “NF1”, which is known to reduce the activity of the RAS protein.

The research group at the Sahlgrenska Academy has previously used two different types of mouse models, one of them with the RAS-mutation and the other with the NF1-mutation. Both mutations individually cause a slowly progressing leukaemia to develop in the mice. The research group has now combined the two animal models and shown that a very aggressive form of acute leukaemia develops in mice with mutations in both genes.

“The corresponding increase in the RAS signalling cannot explain the severe increase in disease aggressiveness, and this means that the NF1 protein may play a different role in the development of the leukaemia than we originally thought and may not involve the RAS protein at all. The discovery opens the possibility of developing new treatments for patients who have mutations in NF1”, says Martin Bergö.

The research group is now collaborating with another research group at the Sahlgrenska Academy, investigating the role that the NF1 protein plays, and how these new results can lead to new treatment strategies.

###

LEUKAEMIA

Around 900 people in Sweden are diagnosed with leukaemia each year. Leukaemias are diseases of the blood that involve the formation of large quantities of white blood cells. The leukaemia cells often invade the liver, spleen and lymph nodes, leading to a seriously impaired immune defence. Considerable progress has been made in research into leukaemia during recent decades, both with respect to treatment and classification, but the fundamental processes remain partially unknown.

For more information, contact:

Associate professor: Martin Bergö, telephone: +46 31 342 7858,
Journal: Blood
Title of the article: NF1 deficiency co-operates with oncogenic K-RAS to induced acute myeloid leukemia in mice
Authors: Briony A. Cutts, Anna-Karin M. Sjögren, Karin M.E. Andersson, Annika M. Wahlström, Christin Karlsson, Birgitta Swolin and Martin O. Bergö

Contact: Elin Lindström Claessen

46-031-786-3869
University of Gothenburg

RELATED STORIES:
Petrochemicals linked to leukemia in young adults   Researchers discover genetic differences between lethal and treatable forms of leukemia   Adult height lower in childhood leukemia survivors   Individualizing Treatment for Multiple Myeloma Patients   X-rays linked to increased childhood leukemia risk   2 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma   Researchers Unlock Mystery of Very Aggressive Leukemia   Immunotherapy demonstrates long-term success in treating lymphoma   Disparities among patients with extremity soft-tissue sarcomas   Mutations Point the Way to New Leukemia Drugs   Stress Hormone May Hasten the Progression of Certain Blood Cancers   Anemia ups hospitalization, death risk for elderly   No link between leukemia risk and nuclear plants   New Therapeutic Options for Newly Diagnosed Multiple Myeloma Patients   Hodgkin’s survivors at increased risk for leukemia   Drug combination shows promise for newly diagnosed blood cancer patients   Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells   Finding indicate why some kinds of Leukemia are more aggressive than others   Childhood Leukemia Survivors Struggle With Long-Term Comorbidities   HK scientists uncover workings behind leukemia   Researchers Seek Alternative for Leukemia Patients Resistant to Standard Therapies   Long-term therapy in the fight against multiple myeloma

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]